Palisade Bio

PALINasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$366.253 M

$2.11 +0.96%

Close of 7 Aug 2026

Revenue

$0.00

#3658 by revenue

Earnings

-$16.8M

Loss-making

Shares outstanding

165,884,817

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#80Compass TherapeuticsCMPX$387.2M
#81Lexeo TherapeuticsLXEO$377.7M
#82Palisade BioPALI$366.3M
#83Century TherapeuticsIPSC$360.7M
#84Fate TherapeuticsFATE$326.4M

Where these numbers come from

Share counts and financials for Palisade Bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.